BerGenBio’s Fourth Quarter 2023 Results: Focused Strategy Gathers Momentum
Bergen (Norway), February 14, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended December 31, 2023, and provided a business update. Highlights, including post period · Phase 1b part of BGBC016 (1L NSCLC STK11m) progressed as planned with no new safety signals identified. · Regulatory approvals received from European countries for Phase 2a part of BGBC016 (1L NSCLC STK11m) allowing initiation in H1 2024 in